Laura Shawver, Silverback CEO
July 21, 2022 04:07 PM EDTUpdated 05:19 PM
Deals

Or­biMed-backed Sil­ver­back, three months af­ter hack­ing the pipeline, re­verse-merges with small al­ler­gy biotech

Paul Schloesser

Associate Editor

Six years af­ter be­ing found­ed, a Seat­tle biotech backed by Or­biMed is say­ing good­bye in a clas­sic re­verse merg­er — while an­oth­er jumps to Nas­daq. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times